| Literature DB >> 26451163 |
Gilberto González-Parra1, Hana M Dobrovolny2.
Abstract
Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and pneumonia in children younger than 1 year of age in the United States. Moreover, RSV is being recognized more often as a significant cause of respiratory illness in older adults. Although RSV has been studied both clinically and in vitro, a quantitative understanding of the infection dynamics is still lacking. In this paper, we study the effect of uncertainty in the main parameters of a viral kinetics model of RSV. We first characterize the RSV replication cycle and extract parameter values by fitting the mathematical model to in vivo data from eight human subjects. We then use Monte Carlo numerical simulations to determine how uncertainty in the parameter values will affect model predictions. We find that uncertainty in the infection rate, eclipse phase duration, and infectious lifespan most affect the predicted dynamics of RSV. This study provides the first estimate of in vivo RSV infection parameters, helping to quantify RSV dynamics. Our assessment of the effect of uncertainty will help guide future experimental design to obtain more precise parameter values.Entities:
Mesh:
Year: 2015 PMID: 26451163 PMCID: PMC4584223 DOI: 10.1155/2015/567589
Source DB: PubMed Journal: Comput Math Methods Med ISSN: 1748-670X Impact factor: 2.238
Figure 1Viral kinetic model. The virus, V, attacks target cells, T, at rate β. Once infected, target cells enter the eclipse phase, E. The eclipse phase lasts an average time of τ , after which the cells become infectious cells, I. The infectious cells produce new virions at rate p, and the virus decays at rate c. The cells remain infectious for an average time of τ , after which they become dead cells.
Figure 2Numerical simulations of the virus kinetic model (1) fitted for different patients. The graphs present viral titers in TCID50/mL of nasal wash (red circles) and the fits.
Estimated parameters for RSV in vivo infection.
| Patient |
|
|
|
|
|
|
| SSR |
|---|---|---|---|---|---|---|---|---|
| (h) | (/h) | (h) | (h) | (h) | (h) | (TCID50/mL/mL) | ||
| 1 | 2.4 | 0.28 | 7.2 | 7.2 | 5.1 | 5.1 | 0.17 | 5.6 |
| 2 | 4.3 | 0.78 | 5.3 | 19 | 2.2 | 11 | 0.010 | 5.3 |
| 3 | 1.9 | 0.13 | 4.8 | 9.6 | 2.8 | 4.8 | 0.013 | 9.5 |
| 4 | 3.8 | 0.20 | 7.9 | 11 | 5.6 | 7.8 | 0.011 | 8.8 |
| 5 | 0.72 | 0.063 | 18 | 24 | 10 | 9.1 | 0.010 | 1.1 |
| 6 | 2.4 | 0.20 | 10 | 17 | 4.5 | 8.5 | 0.012 | 4.3 |
| 7 | 6.2 | 0.096 | 14 | 17 | 9.9 | 9.8 | 0.030 | 0.6 |
| 12 | 1.7 | 0.44 | 13 | 10 | 3.4 | 5.0 | 0.16 | 2.3 |
|
| ||||||||
| Median | 2.4 | 0.20 | 9.0 | 14 | 4.8 | 8.2 | 0.13 | 4.8 |
Patient numbers are those originally found in [27].
Figure 3Fit of the viral kinetics model (1) to median RSV in vivo data.
Figure 4Monte Carlo numerical simulations of the virus kinetic model using the parameter values extracted from the fit to the median virus data. The graphs present the mean (dashed blue line) and 95% confidence interval (solid black lines).